XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Details) - Schedule of segment performance to the GAAP measure of gross profit - USD ($)
 12 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Net sales    
Pocono Pharmaceuticals $ 1,785,597 $ 1,179,620
4P Therapeutics 294,102 242,534
Net sales total 2,079,699 1,422,154
Gross profit    
Pocono Pharmaceuticals 726,702 595,087
4P Therapeutics 23,702 (40,777)
Gross profit total 750,404 554,310
Operating expenses    
Selling, general and administrative-Pocono Pharmaceuticals 577,930 556,204
Selling, general and administrative-4P Therapeutics 103,181 96,079
Corporate overhead 3,234,930 3,370,541
Research and development-4P Therapeutics 982,227 411,383
Goodwill impairment-Pocono Pharmaceuticals 327,326 2,180,836
Non-Operating expenses total 5,225,594 6,615,043
Depreciation and Amortization    
Pocono Pharmaceuticals 264,156 220,524
4P Therapeutics 65,987 88,217
Depreciation and Amortization total $ 330,143 $ 308,741